Novo Nordisk A Slash S

Novo Nordisk A Slash S's reported carbon emissions

Novo Nordisk A/S, a pharmaceutical preparation manufacturing company headquartered in Denmark, has demonstrated a commitment to reducing its carbon footprint. For the reporting year 2025, the company reported total emissions of approximately 2.69 billion kg CO2e. This includes Scope 1 emissions totalling about 120 million kg CO2e, and Scope 2 emissions, using the market-based method, of approximately 63 million kg CO2e. Scope 3 emissions were substantial, amounting to approximately 2.51 billion kg CO2e, with purchased goods and services being the largest contributor at approximately 1.38 billion kg CO2e. In 2024, Novo Nordisk's total emissions were approximately 2.26 billion kg CO2e, comprising 85 million kg CO2e for Scope 1 and approximately 16 million kg CO2e for Scope 2 (market-based). Scope 3 emissions for 2024 were around 2.16 billion kg CO2e. The company has set ambitious climate targets. These include achieving net-zero emissions across its entire value chain by 2045. Furthermore, Novo Nordisk has established a near-term target to reduce its Scope 3 CO2 emissions by 33% by 2033, using 2024 as the base year. They also aim for zero CO2e emissions from operations and transportation by 2030. Several Science Based Targets initiative (SBTi) commitments have been made, including a 100% reduction in absolute Scope 1 and 2 emissions by 2030, with a 2018 base year, and a commitment for key suppliers to have GHG reduction targets by 2030. Additionally, there is a long-term commitment to reduce absolute Scope 3 GHG emissions by 90% by 2045, based on a 2024 baseline.